Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation

2

Department of Internal Medicine, Section of Cardiovascular Medicine, Yale Cardiovascular Research Center, Yale School of Medicine, New Haven, CT

3

Yale Stem Cell Center, Yale School of Medicine, New Haven, CT

7

Vascular Biology and Therapeutics Program, Yale University, New Haven, CT

8

Department of Pathology, Yale University, New Haven, CT

View original article

0 0 0 0 0 0 0

Comments (0)